Triple Agonist (GIP/GLP-1/Glucagon Receptor Agonist): Multi-Receptor Incretin Research

The Evolution from Dual to Triple Agonism

Triple incretin receptor agonists represent the latest evolution in multi-receptor peptide pharmacology. Building on the established dual GIP/GLP-1 agonist concept, these compounds add a third target: the glucagon receptor (GCGR). The rationale emerged from preclinical research demonstrating that glucagon receptor activation drives hepatic lipid oxidation and increases energy expenditure through thermogenic pathways—effects that complement the insulin-sensitizing and appetite-modulating properties of GIP and GLP-1 receptor activation.

Chemical Structure

The triple agonist is a synthetic 39-amino acid peptide (MW ~4.2 kDa) featuring:

• Aib at position 2: DPP-IV resistance, preventing rapid N-terminal degradation
• C18 fatty acid moiety at Lys30: Conjugated via a linker for non-covalent albumin association, extending circulating half-life in pharmacokinetic studies
• Imbalanced agonism profile: Exhibits low-nanomolar potency across all three receptor subtypes in cAMP-based reporter assays, with higher relative activity at GIPR compared to GLP-1R and GCGR

The structural basis for triple receptor cross-reactivity lies in the shared evolutionary origin of the GIP, GLP-1, and glucagon receptors—all three are class B GPCRs with significant extracellular domain homology.

The Three Receptor Targets

GIP Receptor (GIPR)

Mediates glucose-dependent insulin secretion and has emerging roles in adipose tissue metabolism and central nervous system energy balance signaling.

GLP-1 Receptor (GLP-1R)

Potentiates insulin secretion, suppresses glucagon release, and activates hypothalamic satiety circuits. Well-characterized through extensive single-agonist research.

Glucagon Receptor (GCGR)

The distinguishing addition in triple agonists. GCGR activation in hepatocytes stimulates glycogenolysis and gluconeogenesis acutely, but also activates fatty acid oxidation through AMPK-dependent and PPARα-mediated pathways. In preclinical models, glucagon receptor activation increases energy expenditure via brown adipose tissue thermogenesis and hepatic FGF21 secretion.

Key Published Research

• Coskun T et al. (2022) — Published in Nature. Characterized LY3437943 as a novel triple GIP/GLP-1/glucagon receptor agonist. Demonstrated tri-agonist activity in cAMP reporter cell lines and preclinical metabolic models.
• Finan B et al. (2015) — Published in Nature Medicine. Established the triple agonist concept with a rationally designed unimolecular peptide targeting all three receptors. Demonstrated that glucagon receptor inclusion enhances energy expenditure in rodent models.
• Urva S et al. (2022) — Pharmacokinetic and pharmacodynamic characterization in preclinical models.

Future Research Directions

Active areas of investigation include optimizing the relative agonist balance across the three receptors, studying the hepatic signaling consequences of concurrent GLP-1R and GCGR activation, characterizing the FGF21 secretion pathway downstream of glucagon receptor agonism, and developing assay systems for simultaneous three-receptor activity measurement. The relationship between GCGR-mediated energy expenditure and GLP-1R-mediated satiety signaling is a particularly active area.

Available at Crush Research in multiple formats: 10mg, 14mg, 15mg, Triple Agonist R 15mg, and 30mg. View Certificates of Analysis.

All products are intended for in vitro and laboratory research use only. Not for human or veterinary use.